Evoke Pharma Net Worth
Evoke Pharma Net Worth Breakdown | EVOK |
Evoke Pharma Net Worth Analysis
Evoke Pharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Evoke Pharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Evoke Pharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Evoke Pharma's net worth analysis. One common approach is to calculate Evoke Pharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Evoke Pharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Evoke Pharma's net worth. This approach calculates the present value of Evoke Pharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Evoke Pharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Evoke Pharma's net worth. This involves comparing Evoke Pharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Evoke Pharma's net worth relative to its peers.
Enterprise Value |
|
To determine if Evoke Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Evoke Pharma's net worth research are outlined below:
| Evoke Pharma had very high historical volatility over the last 90 days | |
| Evoke Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 5.18 M. Net Loss for the year was (7.79 M) with profit before overhead, payroll, taxes, and interest of 2.14 M. | |
| Evoke Pharma currently holds about 13.45 M in cash with (4.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.02. | |
| Latest headline from MacroaxisInsider: Insider Trading |
Evoke Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Evoke Pharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Evoke Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Evoke Pharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Evoke Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Evoke Pharma backward and forwards among themselves. Evoke Pharma's institutional investor refers to the entity that pools money to purchase Evoke Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Aigh Capital Management, Llc | 2024-09-30 | 70.5 K | Bleichroeder Lp | 2024-09-30 | 68.8 K | Nantahala Capital Management, Llc | 2024-09-30 | 56.2 K | Citigroup Inc | 2024-09-30 | 4.0 | Goldman Sachs Group Inc | 2024-06-30 | 0.0 | Millennium Management Llc | 2024-06-30 | 0.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Federation Des Caisses Desjardins Du Quebec | 2024-06-30 | 0.0 |
Follow Evoke Pharma's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.46 M.Market Cap |
|
Project Evoke Pharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.10) | (1.16) | |
| Return On Capital Employed | (1.84) | (1.93) | |
| Return On Assets | (1.10) | (1.16) | |
| Return On Equity | 3.02 | 3.17 |
When accessing Evoke Pharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Evoke Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Evoke Pharma's profitability and make more informed investment decisions.
Evaluate Evoke Pharma's management efficiency
Evoke Pharma has return on total asset (ROA) of (0.335) % which means that it has lost $0.335 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.4991) %, meaning that it created substantial loss on money invested by shareholders. Evoke Pharma's management efficiency ratios could be used to measure how well Evoke Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is expected to rise to 3.17 this year, although the value of Return On Tangible Assets will most likely fall to (1.16). At this time, Evoke Pharma's Liabilities And Stockholders Equity is quite stable compared to the past year. Change To Liabilities is expected to rise to about 101.4 K this year, although the value of Total Current Liabilities will most likely fall to about 2.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (9.26) | (9.72) | |
| Tangible Book Value Per Share | (9.26) | (9.72) | |
| Enterprise Value Over EBITDA | (0.52) | (0.54) | |
| Price Book Value Ratio | (1.36) | (1.29) | |
| Enterprise Value Multiple | (0.52) | (0.54) | |
| Price Fair Value | (1.36) | (1.29) | |
| Enterprise Value | 3.8 M | 3.6 M |
The management team at Evoke Pharma has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Enterprise Value Revenue 0.0111 | Revenue 8.6 M | Quarterly Revenue Growth 0.698 | Revenue Per Share 7.792 | Return On Equity (3.50) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Evoke Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Evoke Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Evoke Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Nantahala Capital Management, Llc a day ago Insider Trading | ||
Nantahala Capital Management, Llc 2 days ago Insider Trading | ||
Nantahala Capital Management, Llc 3 days ago Insider Trading | ||
Nantahala Capital Management, Llc few days ago Insider Trading | ||
Nantahala Capital Management, Llc few days ago Insider Trading | ||
Nantahala Capital Management, Llc few days ago Insider Trading | ||
Nantahala Capital Management, Llc six days ago Insider Trading | ||
Nantahala Capital Management, Llc over a week ago Insider Trading | ||
Nantahala Capital Management, Llc over a week ago Insider Trading | ||
Nantahala Capital Management, Llc over a week ago Insider Trading | ||
Nantahala Capital Management, Llc over a week ago Insider Trading | ||
Nantahala Capital Management, Llc over two weeks ago Insider Trading |
Evoke Pharma Corporate Filings
| 22nd of November 2024 Other Reports | ViewVerify | |
F3 | 15th of November 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 7th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Evoke Pharma Earnings per Share Projection vs Actual
Evoke Pharma Corporate Management
| Mark CPA | Chief Officer | Profile | |
| DMD MD | Chief Officer | Profile | |
| Christopher Quesenberry | Chief Gimoti | Profile | |
| Marilyn Carlson | Chief Medical Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evoke Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. If investors know Evoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evoke Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.13) | Revenue Per Share 7.792 | Quarterly Revenue Growth 0.698 | Return On Assets (0.34) | Return On Equity (3.50) |
The market value of Evoke Pharma is measured differently than its book value, which is the value of Evoke that is recorded on the company's balance sheet. Investors also form their own opinion of Evoke Pharma's value that differs from its market value or its book value, called intrinsic value, which is Evoke Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evoke Pharma's market value can be influenced by many factors that don't directly affect Evoke Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evoke Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evoke Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evoke Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.